Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis to buy radiology specialist Mariana Oncology for $1 billion
07:18am, Thursday, 02'nd May 2024
Novartis has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for $1 billion, the Swiss drug manufacturer said on Thursday.
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
07:18am, Thursday, 02'nd May 2024
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
MorphoSys: Hold Rating Until The Novartis Deal Closes
08:36pm, Tuesday, 30'th Apr 2024
MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals receiv
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
07:00am, Tuesday, 30'th Apr 2024
KAWASAKI, Japan--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today annou
Morphosys says Novartis takeover progressing as planned for H1 2024
05:11am, Monday, 29'th Apr 2024
Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT New
16 High-Yield Dividend Aristocrats Yielding Almost 5%
07:00am, Saturday, 27'th Apr 2024
Attempting to time the market is not a successful strategy. Long-term investing has consistently outperformed market timing. Today, the S&P is fairly valued, but blue-chip bargains are plentiful if yo
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies
12:30am, Wednesday, 24'th Apr 2024
Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-
Why Novartis Stock Topped the Market on Tuesday
06:25pm, Tuesday, 23'rd Apr 2024
The pharmaceutical sector mainstay posted its first-quarter results. It beat on both the top and bottom lines.
Novartis raises full-year sales and profit guidance after strong Q1
02:10pm, Tuesday, 23'rd Apr 2024
Novartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong first quarter driven by momentum in key products including psoriasis drug Cosentyx, relapsing Multi
Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for th
Novartis CEO: Here's why we boosted our full-year guidance
01:39pm, Tuesday, 23'rd Apr 2024
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
12:30pm, Tuesday, 23'rd Apr 2024
American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its guidan
Novartis AG (NVS) Q1 2024 Earnings Call Transcript
11:55am, Tuesday, 23'rd Apr 2024
Novartis AG (NYSE:NVS ) Q1 2024 Earnings Conference Call April 23, 2024 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
10:36am, Tuesday, 23'rd Apr 2024
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
10:01am, Tuesday, 23'rd Apr 2024
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
